Tens of thousands of unnecessary operations are performed each year for diagnostic purposes among patients with cytologically indeterminate thyroid nodules. Whereas a diagnostic lobectomy is recommended for most patients with solitary indeterminate thyroid nodules, a total thyroidectomy is preferred for nodules larger than 4 cm.
E ach year more than 60 000 operations for histologically benign thyroid nodules are unnecessarily performed for diagnostic purposes among patients with cytologically indeterminate thyroid nodules (ITNs) (eg, atypia or follicular lesion of undetermined significance or follicular or Hürthle cell neoplasm of the Bethesda System for Reporting Thyroid Cytopathology [hereafter referred to as the Bethesda system]). 1, 2 When surgery is indicated, a diagnostic lobectomy is generally the recommended approach for patients with solitary ITNs. 3 The 2015 American Thyroid Association (ATA) guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer (DTC) suggest, however, that a total thyroidectomy may be preferred in certain situations in which risk of cancer is increased, particularly if, in the event of being malignant, a completion thyroidectomy would be indicated (recommendation 20.a). 3 Large tumor size (ie, >4 cm) has been traditionally associated with an increased risk of cancer even after a benign or indeterminate cytologic result, 4,5 and a total thyroidectomy is currently the preferred treatment option for DTCs larger than 4 cm. For this reason, the ATA guidelines suggest that a total thyroidectomy may be the preferred surgical approach for ITNs larger than 4 cm.
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Several recent developments prompted us to reevaluate this recommendation. First, the recognition that, because of the indolent behavior of most thyroid cancers, less initial treatment is often better because more extensive resections in lowrisk cancers are associated with an increased complication rate without improving survival. 6, 7 This concept has been the driving force for many of the changes presented in the latest version of the ATA guidelines. 3 Second, increasing evidence suggests that most malignant tumors diagnosed after indeterminate cytologic results are low risk. These cancers have significantly better prognosis than those found in lesions with cytologic results diagnostic of or suspicious for cancer. [8] [9] [10] [11] Third, a large paradigm shift occurred in the diagnostic criteria for thyroid cancer, with almost 40% of ITNs formerly called cancer now being reclassified as premalignant, for which a diagnostic lobectomy is considered to be sufficient treatment. [12] [13] [14] This study aimed to determine whether histologic or follow-up outcomes of ITNs 4 cm or larger are worse than for nodules smaller than 4 cm, thus justifying a more aggressive initial surgical approach.
Methods

Study Cohort
Electronic medical records of patients with ITNs evaluated from October 1, 2008 , through April 30, 2016 , at the H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, were retrospectively reviewed. Of 1053 ITNs, 24 (2.3%) had presurgical evidence of cancer and were excluded from the study: 5 had vocal cord paralysis, 14 had proven cervical lymph node metastasis, 1 had vocal cord paralysis and proven cervical lymph node metastasis, 1 had proven distant metastasis, 2 had elevated basal serum calcitonin level (>100 pg/mL [to convert to picomoles per liter, multiply by 0.292]), and 1 had explosive growth. In addition, 371 ITNs (35.2%) without histologic correlation (no surgical follow-up or unknown histologic type of the biopsied nodule) and 6 (0.6%) without presurgical size available were excluded. Finally, 652 ITNs (61.9%) in 589 patients were included in the study. The University of South Florida Institutional Review Board provided a waiver of consent for this study.
Pathologic Characterization
All cytologic diagnoses were issued by board-certified cytopathologists at our institution according to the Bethesda system and were abstracted from the reports. For nodules with multiple biopsy specimens, the most recent was used for the analyses. Histologic diagnoses were retrieved from reports issued before February 2017 at the pathology department at H. 
Molecular Characterization
Oncogene panels were used selectively since the middle of 2012 and consistently since 2014 for the evaluation of ITNs at our
Key Points
Question Should tumor size determine the extent of surgery for cytologically indeterminate thyroid nodules?
Findings In this cohort study of 652 indeterminate thyroid nodules, more than 90% of indeterminate thyroid nodules were benign or low-risk malignant tumors for which a lobectomy would be sufficient initial treatment regardless of tumor size. Tumor size was not associated with cancer rates, cancer aggressiveness, or response to therapy.
Meaning
In the absence of other indications for total thyroidectomy, this study suggests that the preferred surgical approach for cytologically indeterminate thyroid nodules is a thyroid lobectomy regardless of tumor size.
institution. A 7-gene oncogene panel (miRInform, Asuragen, in all but 1 patient) was used until September 2014, and results were considered to be positive if any of the 14 point mutations or 3 gene rearrangements were identified by the test.
17
ThyroSeq version 2 (University of Pittsburgh Medical Center and CBLPath Inc) was used thereafter, and results were considered to be positive if a genetic alteration (>1000 hotspots in 14 genes and 42 gene rearrangements) was identified at an allelic frequency greater than 5% or 10%, depending on the mutation as described in the original validation studies. [18] [19] [20] Although resection rates were lower for test-negative nodules than for test-positive nodules, tests results were used primarily to determine the extent of surgery rather than to avoid resection, in accordance with the guidelines' recommendations at the time.
21,22
Statistical Analysis Locoregional or distant involvement was infrequent among malignant tumors (Table 3) . No differences (weak associations) were found in the proportion of nodules with extrathyroidal extension, positive surgical margins, lymph node metastasis, or distant metastasis between the 2 groups. A weak association was found between the presence of distant metastasis and larger malignant tumors (effect size, 0.16; 95% CI, 0.01-0.30). A lobectomy may have been appropriate for more than 90% of all ITNs (with benign histologic findings or lowrisk malignant tumors, which included NIFTPs) if size was not taken into account to decide the extent of surgery. High-risk features were found in 5 cases (0.8%), including the 2 medullary thyroid carcinomas.
Follow-up Findings
There were 164 patients with 167 foci of DTC in this cohort. Seventeen malignant tumors with another thyroid cancer focus (which could act as a confounding factor) and 17 malignant tumors with less than 6 months of follow-up were excluded. Follow-up outcomes were finally retrieved from 105 patients with DTCs smaller than 4 cm and 25 patients with DTCs 4 cm or larger ( Table 4) . The median follow-up time was 36 months, with no differences between groups (37 months for patients with DTCs <4 cm and 33 months for patients with DTCs ≥4 cm; effect size, 4.0; 95% CI, −5.0 to 17.5). No recurrences occurred in any of the groups during follow-up, and no differences were found in the response to therapy between the groups (effect size, 0.13; 95% CI, 0.07-0.33). Most patients had excellent response (no evidence of disease) at the last follow-up visit (88 of 105 patients [83.8%] in the <4-cm group and 21 of 25 [84.0%] in the ≥4-cm group). Similar outcomes were observed if patients with other concurrent thyroid cancer foci were included (eTable 2 in the Supplement).
Size as a Continuous Variable
Size as a continuous variable was not associated with the risk of cancer (OR, 1.03; 95% CI, 0.92-1.15) or with the aggressiveness of cancers. Compared with the odds of the nodule being low-risk cancer, for each unit increase in size, there was a nonstatistically significant 43% increase in the odds of the nodule being high-risk cancer (OR, 1.43; 95% CI, 0.96-2.15) and a non-statistically significant 9% decrease in the odds of the nodule being intermediate-risk cancer (OR, 0.91; 95% CI, 0.72-1.14). The size metrics of each histologic diagnosis are summarized in Table 2 . Among all possible pairwise comparisons in size (eTable 3 in the Supplement), the following Cohen d effect sizes were large: non-FVPTC PTCs (other PTCs) were smaller than adenomas (effect size, 1.01; 95% CI, 0.68-1.34), NIFTPs (effect size, 0.89; 95% CI, 0.48-1.30), FVPTCs (effect size, 1.04; 95% CI, 0.58-1.50), follicular thyroid carcinomas (effect size, 1.67; 95% CI, 0.68-1.34), and nonfollicular cellderived cancers (other) (effect size, 1.63; 95% CI, 0.71-2.55), and hyperplastic and adenomatoid nodules were smaller than follicular thyroid carcinomas (effect size, 1.03; 95% CI, 0.61-1.45) and nonfollicular cell-derived cancers (other) (effect size, 1.07; 95% CI, 0.25-1.89). The effect sizes of all other possible pairwise comparisons were small or medium.
Discussion
In this series, ITN size of 4 cm or larger was not associated with an increased risk of cancer, cancer aggressiveness, or worse outcomes. In fact, most ITNs, regardless of nodule size, were benign or low-risk malignant tumors for which a lobectomy could be a sufficient initial treatment.
The rate of cancer for indeterminate categories at our institution, considering NIFTPs as benign or malignant, are within the expected and previously reported values, 25 and the histologic diagnoses and mutational profiles in this series are consistent with those of previously published cohorts of cytologically ITNs. 10, 18, 19, 26 We believe that despite the inherent design First, most malignant ITNs are low-risk malignant tumors. Histologic and molecular findings of malignant ITNs have been suggested to be different from other malignant tumors with more definitive cytologic results (ie, suspicious for cancer or diagnostic of cancer). [8] [9] [10] [11] In the former, most mutations are RAS like, which are generally associated with better differentiated follicular pattern tumors, whereas in the latter, BRAF-like mutations are the most prevalent and frequently associated with a poorer thyroid differentiation score and PTC. [28] [29] [30] [31] [32] In previous studies from our institution, 17,20,22 the genetic background of ITNs was consistent with this expecta- tion, with approximately 60% of identified mutations being in the RAS genes. The present study found that most malignant tumors among the indeterminate cytologic categories were low-risk follicular-pattern lesions (including NIFTPs and minimally invasive follicular thyroid carcinomas), which is also consistent with previous series. [8] [9] [10] [11] This study adds to the current knowledge that, among larger tumors, low-risk cancers are the most prevalent malignant tumors. Second, the NIFTP reclassification affected the institutional cancer rates. Soon after the introduction of the Bethesda system, it became clear that there were wide interinstitutional variations in the rate of cancer of the indeterminate categories. 27 The interpretation of noninvasive follicular pattern lesions as follicular adenomas or follicular variant of papillary thyroid carcinomas (now NIFTPs) seem to be a significant source of disagreement. 12, [33] [34] [35] For this reason, the interinstitutional variability in the rates of cancer of the indeterminate cytologic categories should be significantly decreased if NIFTPs are no longer considered to be malignant. This speculation, however, remains to be proven. The present study did not find differences in the rate of cancer calculated with or without NIFTPs between the 2 groups. Unlike this study, a recent meta-analysis 4 of 646 ITNs from 5 studies found an increased risk of cancer for ITNs larger than 4 cm compared with smaller ITNs. The studies in that meta-analysis were published before the reclassification of encapsulated noninvasive FVPTCs as NIFTPs, however, and the heterogeneity in the rates of cancer was significant. A new evaluation that excludes NIFTPs from the calculation of the rate of cancer might be necessary to clarify how size affects cancer risk among ITNs. Third, total thyroidectomy is no longer recommended for all DTCs larger than 1 cm. The 2015 ATA guidelines consider that a lobectomy may be sufficient initial treatment for intrathyroidal DTCs smaller than 4 cm, NIFTPs of any size, and minimally invasive follicular thyroid carcinomas and intrathyroidal encapsulated FVPTCs. 3, 36 This treatment de-escalation for low-risk malignant tumors is supported by 2 facts: surgical extent does not seem to affect survival or recurrence rates 37, 38 and the complication rate of thyroid lobectomies is half that of total thyroidectomies (11% vs 20%). 7 Furthermore, a more conservative resection allows preserving thyroid function in approximately 80% of cases, 39 and, if needed, the outcomes and complication rate of a 2-step thyroidectomy are similar to those of a total thyroidectomy. 40 In this context, in which the presence of aggressive clinicopathologic features rather than the expected rate of cancer drives the surgical plan to minimize overtreatment, it seems contradictory that a total thyroidectomy be recommended on the sole basis of size larger than 4 cm given that 70% of ITNs are expected to be histologically benign. In this study, we found no association between tumor size and cancer aggressiveness, using size as a continuous variable or as a binary variable with the currently accepted size threshold (4 cm). On the basis of histologic findings, a lobectomy could have been sufficient initial treatment for more than 90% of the ITNs in this cohort regardless of size.
Limitations
We recognize that a type II error is possible because of the limited number of malignant tumors 4 cm or larger and the limited number of high-risk cancers in this cohort. The only patient with distant metastasis had a 6.8-cm FVPTC with capsular and vascular invasion and mutations in the NRAS, TERT (OMIM 187270), and EIF1AX (OMIM 300186) genes detected in a presurgical fine-needle aspiration biopsy specimen. Follow-up time might be short to detect recurrences in DTCs. The risk of recurrence in this series, however, is expected to be low because 84% of the malignant tumors were in patients with no evidence of disease at last follow-up visit.
3
The cytologic features of all ITNs included in this series were consecutively evaluated, and 97% of the histologic diagnoses were issued by board-certified pathologists at an academic cancer center, which strengthens the reliability of the pathologic diagnoses. Furthermore, the histologic specimens of 96% of the FVPTCs diagnosed before the proposed change in nomenclature for encapsulated and noninvasive tumors into NIFTPs were re-reviewed to ensure adherence with current diagnostic criteria. Nonetheless, we recognize the limitations of light microscopy.
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Conclusions
Malignant tumors of any size with indeterminate cytologic findings are usually well-differentiated, low-risk follicularpattern tumors with excellent outcomes. Thus, recommending a total thyroidectomy for ITNs on the basis of tumor size may lead to overtreatment in a significant proportion of pa- tients, unnecessarily exposing them to surgical risks and complications and to the need for lifelong thyroid hormonereplacement therapy. Because the expected risk from cancer (rather than the expected risk of cancer) drives the current surgical recommendations, this study suggests that in the absence of other indications for total thyroidectomy, a therapeutic or diagnostic lobectomy would be appropriate for more than 90% of solitary ITNs regardless of tumor size. In response to this, encapsulated follicular variant of papillary thyroid cancer (EFVPTC) has recently been reclassified as noninvasive follicular thyroid neoplasm with papillarylike nuclear features (NIFTP), a nonmalignant diagnosis because of increasing evidence of indolent behavior.
2 This paradigm shift has led to major shifts in institutional cancer rates for indeterminate thyroid nodules, with a previous study 3 reporting a relative decrease in the risk of cancer up to 50% among patients with indeterminate fine-needle aspiration biopsy findings. Current guidelines suggest that diagnostic thyroid surgery may be considered as initial management for indeterminate thyroid nodules if the nodules are smaller than 4 cm, and total thyroidectomy may be considered for larger nodules (>4 cm) because of the increased risk of cancer.
4 Total thyroidectomy is not without consequence and has a higher risk of complication than lobectomy even among experienced surgeons. 5 Furthermore, the increased risk of cancer among large nodules was reported in studies 6,7 before the reclassification of EFVPTC as NIFTP; thus, the correlation between nodule size and malignant potential warrants reexamination. For this reason, Valderrabano et al 8 conducted a welltimed study investigating the association of nodule size with clinical and pathologic outcomes in patients with cytologically indeterminate lesions in the NIFTP era. In this study, 8 652 nodules with indeterminate cytologic findings (Bethesda system category III/IV) were grouped according to size (<4 or ≥4 cm) and compared by overall cancer rates and histopathologic aggressiveness. Nodules with the ultimate diagnosis of EFVPTC were reviewed and reclassified as NIFTP or papillary thyroid cancer. No differences were found in the prevalence of malignant nodules between groups, and size was not associated with increased risk of cancer when analyzed as a continuous variable. No differences were found in the proportion of nodules with locoregional or distant involvement between the groups. On follow-up, no recurrences and no significant differences in response to therapy were found in either group. The presence of substantial changes in institutional cancer rates after NIFTP reclassification was revealed in this study. Of the 652 nodules examined, 173 (26.5%) were histologically malignant by previous definition. However, with NIFTPs excluded, only 114 (17.5%) of these nodules were considered to be malignant. There was no difference in cancer rates when 
